ONCOLYTICS BIOTECH INC. overview

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors PR Newswire SAN DIEGO and CALGARY, AB, Sept. 7, 2022 Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB , Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Jonathan Rigby to its Board of Directors. "Jonathan has successfully...

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights PR Newswire SAN DIEGO and CALGARY, AB, Aug. 11, 2022 Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients Clinical biomarker...

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights PR Newswire SAN DIEGO and CALGARY, AB, Aug. 11, 2022 Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients Clinical biomarker...

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights PR Newswire SAN DIEGO, CA and CALGARY, AB, July 27, 2022 Conference call and webcast to take place on Thursday, August 11, 2022 , at 8:30 a.m. ET SAN DIEGO, CA and CALGARY, AB , July 27, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, August 11, 2022 , at 8:30 a.m. ET to...

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET PR Newswire SAN DIEGO and CALGARY, AB, June 28, 2022 Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment Data suggest pelareorep synergistically combines with chemotherapy and checkpoint inhibition in a highly challenging indication and are featured in an abstract at the ESMO...

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference PR Newswire SAN DIEGO, Calif. and CALGARY, AB, May 10, 2022 SAN DIEGO, Calif. and CALGARY, AB , May 10, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey , President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference, which is taking place May...

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights PR Newswire SAN DIEGO, Calif and CALGARY, AB, May 5, 2022 Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's induced improvement in the prognosis of HR+/HER2- breast cancer patients by decreasing their risk of recurrence Preclinical data...

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting PR Newswire SAN DIEGO and CALGARY, AB, May 4, 2022 Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant increases in markers of tumor cell death and T cell activation...